Lipocine Announces Regulatory Path Forward for TLANDO™ Resubmission
SALT LAKE CITY, Feb. 24, 2020 /PRNewswire/ — Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the results of its Post Action meeting with the U.S. Food and Drug Administration (“FDA’) regarding its New Drug…
Comments Off on Lipocine Announces Regulatory Path Forward for TLANDO™ Resubmission